Keith Katkin

October 6, 2026

EBS Shares Rise 14.4% After Russia Plague Lab Worker Death. EBS stock jumped 14.4% following the death of a Russian plague laboratory worker, a move that also lifted other vaccine makers such as Novavax, Arcturus and Moderna. The rally has drawn attention from retail traders who are looking for potential contract awards. The shares are currently trading near the $7.98 support level, which has been tested 20 times, and the RSI sits at 55.1, indicating neither overbought nor oversold conditions.

October 13, 2026

SNDX Drops After Axatilimab IPF Trial Misses Endpoint. Syndax Pharmaceuticals stock fell sharply after topline results from the MAXPIRe Phase 2 trial showed axatilimab did not meet its primary endpoint in idiopathic pulmonary fibrosis. The negative data triggered a significant selloff, with the stock dropping as much as 16% in after-hours trading. While some analysts maintain price targets, the trial outcome has raised questions about the drug's potential in this indication.

September 27, 2026

ELDN Presents Phase 2 Data, Gets FDA Fast Track for Tegoprubart. Eledon presented updated long‑term results from its Phase 2 BESTOW extension study at the International Congress of The Transplantation Society. The data support the continued development of tegoprubart for kidney transplant patients. The FDA also granted Fast Track designation for tegoprubart, and the company plans to start a Phase 3 LEGACY study in the fourth quarter of 2026. These milestones highlight progress in the company’s clinical program.